GCGustav Christensen

Gustav Christensen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gustav Christensen has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Antihypertensive Medication as a Risk Factor For Basal Cell Carcinoma: A Nationwide Registry-based Case-control Study

    by Johan Kappelin, Ingela Ahnlide, Gustav B. Christensen, Åsa Ingvar, Kari Nielsen

    Hydrochlorothiazide has been associated with increased cutaneous squamous cell carcinoma risk. Meanwhile, its association with basal cell carcinoma (BCC) risk is controversial. The association between commonly prescribed antihypertensive medications and BCC risk in the Swedish population was investigated. All cases with a histopathologically verified BCC in Sweden during 2007–2017 and 2 matched controls per case were included in this nationwide, registry-based, case-control study. Information on prescribed anti-hypertensive drugs, comorbidities, co-medications, and socioeconomic factors was retrieved from nationwide registries. The odds of being treated with any of the chosen treatments in relation to BCC diagnosis were estimated. In total, 133,539 cases and 257,849 controls were studied. Thiazide-containing combination treatments (OR 1.09), angiotensin II receptor blockers (OR 1.09), calcium channel blockers (OR 1.09), and beta-blockers (OR 1.07) were associated with an increased BCC risk. Use of single-agent thiazide treat-ment did not affect BCC risk. In conclusion, statistically significant associations were found between several commonly prescribed antihypertensives and an increased BCC risk. Thiazide treatment affected BCC risk only when given as combination treatment, indicating that relevant adjunctive substances should be studied further in relation to BCC risk. Presently, it is suggested that prevention efforts focus on UV protection rather than altering antihypertensive treatments.


  • Open Access

    Response to Birrell SN: Commentary on “Photosensitizing Drugs and Risk of Skin Cancer in Women”

    by Kari Nielsen, Åsa Ingvar, Johan Kappelin, Jenny Sandgren, Gustav Christensen

  • Open Access

    Photosensitizing Drugs and Risk of Skin Cancer in Women—A Prospective Population‐Based Study

    by Gustav Boelsgaard Christensen, Johan Kappelin, Jenny Sandgren, Kari Nielsen, Åsa Ingvar

    Background: Several widely used drugs have photosensitizing properties, and much research has been conducted to find associations between their use and the risk of developing cutaneous malignant melanoma (cM), basal cell carcinoma (BCC) or cutaneous squamous cell carcinoma (cSCC), often with conflicting results.Objective: To assess whether the use of commonly prescribed photosensitizing drugs increases skin cancer risk.Methods: Analyses were performed using a large cohort of women, with prospectively collected information on phenotypic traits and sun exposure. Comprehensive information on pharmaceutical treatments and skin cancer occurrence was obtained through national registries. Drugs with photosensitizing properties were grouped according to the Anatomical Therapeutic Chemical system in nine groups, and associations between the use of such drugs were investigated using multivariable Cox regression analysis. The number of retrieved daily doses was analyzed to test the dose–response relationship.Results: Hormone replacement therapy significantly increased the risk of BCC (hazard ratio [HR] 1.24; 95% confidence interval [CI]: 1.11–1.39), cSCC (HR 1.23; 95% CI: 1.03–1.47) and cM (HR 1.31; 95% CI: 1.01–1.69), with estrogen driving this risk. There was a trend of increased risk of BCC and cM with higher doses of estrogen treatment. Subgroup analysis among those using diuretics showed that loop diuretics were associated with increased cSCC risk (HR 1.6; 95% CI: 1.3–2.0), including a positive association between risk and dose. Furthermore, increased risks of BCC (HR 1.25; 95% CI: 1.09–1.44) and cM (HR 1.41; 95% CI: 1.03–1.93) were associated with thiazide use. NSAIDs showed a possible curvilinear association to BCC and cSCC.Conclusions: Estrogen treatment increased the risk of all investigated skin cancers. Among those using diuretics, loop diuretics increased the risk of cSCC, and thiazide use increased the risk of BCC. We suggest that physicians should advise female patients prescribed estrogen, thiazides, or loop diuretics to limit their sun exposure.


  • Open Access

    Clinical performance of a novel hyperspectral imaging device for cutaneous melanoma and pigmented skin lesions in Caucasian skin

    by Gustav Boelsgaard Christensen, Takashi Nagaoka, Yoshio Kiyohara, Iva Johansson, Christian Ingvar, Atsushi Nakamura, Takayuki Sota, Kari Nielsen

    Background: The quest for diagnostic tools for the detection of cutaneous malignant melanoma (cMM) is ongoing. A challenge in cMM care is not overlooking cMM at an early stage, while simultaneously avoiding unnecessary biopsies or excisions of benign pigmented skin lesions (PSLs). A novel hyperspectral imaging (HSI) device is shown to have potential for differentiating equivocal PSLs in Asian skin types. Our objective was to assess the accuracy of the HSI device in distinguishing between cMM and benign PSLs in patients with Caucasian skin types.Methods: Patients with Caucasian skin types (Fitzpatrick I‐II), enrolled for excisional biopsies of PSLs were included and examined using the HSI device. The discrimination index (DI) was used to demonstrate the sensitivity (SE) and specificity (SP) in comparison with the re‐evaluated histopathology diagnoses.Results: In 186 patients, 202 pigmented skin lesions were included. The sensitivity to detect cMM was 96.7% (87/90), and the specificity for benign lesions was 42.1% (45/107). The AUC was 0.800 (95% confidence interval (CI): 0.740‐0.861).Conclusions: Our novel HSI device showed a high sensitivity in detecting malignant lesions in patients with Caucasian skin types. Compared with analogous technologies, as multispectral imaging or electrical impedance spectroscopy, our device showed similar or better accuracy in differentiating cMM from benign PSLs. Therefore, it might be a useful clinical tool in skin types I‐IV and where further triage of pigmented skin lesions is important.


  • Open Access

    Tumor genetic heterogeneity analysis of chronic sun‐damaged melanoma

    by Adriana Sanna, Katja Harbst, Iva Johansson, Gustav Christensen, Martin Lauss, Shamik Mitra, Frida Rosengren, Jari Häkkinen, Johan Vallon‐Christersson, Håkan Olsson, et al.

    Chronic sun‐damaged (CSD) melanoma represents 10%–20% of cutaneous melanomas and is characterized by infrequent BRAF V600E mutations and high mutational load. However, the order of genetic events or the extent of intra‐tumor heterogeneity (ITH) in CSDhigh melanoma is still unknown. Ultra‐deep targeted sequencing of 40 cancer‐associated genes was performed in 72 in situ or invasive CMM, including 23 CSDhigh cases. In addition, we performed whole exome and RNA sequencing on multiple regions of primary tumor and multiple in‐transit metastases from one CSDhigh melanoma patient. We found no significant difference in mutation frequency in melanoma‐related genes or in mutational load between in situ and invasive CSDhigh lesions, while this difference was observed in CSDlow lesions. In addition, increased frequency of BRAF V600K, NF1, and TP53 mutations (p < .01, Fisher's exact test) was found in CSDhigh melanomas. Sequencing of multiple specimens from one CSDhigh patient revealed strikingly limited ITH with >95% shared mutations. Our results provide evidence that CSDhigh and CSDlow melanomas are distinct molecular entities that progress via different genetic routes.


  • Open Access

    Sunbed Use Increases Cutaneous Squamous Cell Carcinoma Risk in Women: A Large-scale, Prospective Study in Sweden

    by G Christensen, C Ingvar, L Hartman, H Olsson, K Nielsen

    The incidence of cutaneous squamous cell carcinoma has increased rapidly in Sweden in the past decad...


  • Open Access

    Pancreatic cancer occurrence in Ferguson-Smith syndrome

    by Karim Saleh, Samuel Gebre-Medhin, Gustav Christensen